CpG ODN对胰腺癌细胞PANC1吉西他滨化疗敏感性的影响

目的 观察用Toll样受体9（TLR9）激动剂CpG ODN2216处理后胰腺癌PANC1细胞对吉西他滨化疗敏感性的影响.方法 采用免疫荧光化学法及蛋白质印迹法检测胰腺癌PANC1细胞TLR9蛋白的表达,应用四甲基偶氮唑蓝（MTT）比色法检测CpG ODN2216处理后PANC1细胞对不同浓度吉西他滨敏感性的变化.结果 胰腺癌PANC1细胞高表达TLR9蛋白.CpG ODN2216±吉西他滨组的PANC1细胞对吉西他滨的半数抑制剂量（IC50）为（0.28 ±0.13） mg/L,吉西他滨组PANC1细胞的IC5o为（1.23±0.14） mg/L,两组差异有统计学意义（P＜0.01）.0.01、0.1、1、10 mg/L吉西他滨干预经CpGODN2216处理的PANC1细胞的生长抑制率分别为（34.1±1.3）％、（43.5±2.7）％、（76.3±2.5）％、（95.3±2.2）％;干预未经CpG ODN2216处理的PANC1细胞的生长抑制率分别为（14.5±0.9）％、（23.5±1.1）％、（44.8±1.4）％、（63.6±1.8）％,两组差异均有统计学意义（P值均＜0.01）.结论 TLR9激动剂CpG ODN2216能增加人胰腺癌细胞PANC1对吉西他滨的敏感性.

Effect of CpG ODN on pancreatic cancer cell line PANC1 sensitivity to gemcitabine

Objective To investigate the effects of toll-like receptor 9 （TLR9） agonist CpG ODN2216 on the sensitivity of pancreatic cancer cell line PANC1＇s to gemcitabine.Methods The immunofluorescence staining method and Western blot method were used to examine the expression of TLR9 protein in PANC1 cells.The changes of sensitivity to gemcitabine after CpG ODN2216 treatment were examined by MTT assay.Results The TLR9 protein was highly expressed in PANC1 cells and the median inhibition concentration of gemcitabine against PANC1 cells was reduced from （1.23 ± 0.14） mg/L to （0.28 ± 0.13） mg/L after CpG ODN2216 treatment,and the difference between the two groups was statistically significant （P ＜0.01）.After 0.01,0.10,1.00,10.00 mg/L gemcitabine treatment with CpG 0DN2216,the inhibition rates of PANC1 were （34.4 ±1.3）％,（43.5 ± 2.7）％,（76.3 ± 2.5）％,（95.3 ± 2.2）％ ; and without CpG ODN2216,the inhibition rates of PANC1 were （14.5 ± 0.9） ％,（23.5 ± 1.1） ％,（44.8 ± 1.4） ％,（63.6 ± 1.8） ％,and the difference between the two groups was statistically significant （P ＜ 0.01）.Conclusions The sensitivity of PANC1 cells to gemcitabine can be enhanced by CpG ODN2216.